The world of the twenty-first century is marked by technological changes and paradigms that are rapidly shaping a new stage of humanity, the era of Artificial Intelligence. Change brings opportunities and challenges. The pharmaceutical industry is adapting to the new and is under enormous pressure to accelerate the development of new drugs and treatments, the period of the global Covid 19 pandemic can be considered a true research marathon. Globalization brings huge competition to the drug market, and all companies are adapting to a reduction in costs and strong budget control. In this context, improving the success rate of clinical trials becomes a strategic objective of pharmaceutical companies. Clinical trials are known to be expensive, but also with long modeling, implementation and evaluation time, from 3 to 10 years. These are not the only constraints. The success rate is low, clinical trials are prone to failures. This is normal. Research does not always imply a positive result. A clinical trial does not bring certainty that that cell or medication will reach the market. The purpose of clinical trials is also to demonstrate what cannot or is not allowed, not only the added therapeutic value to a disease. Artificial Intelligence becomes a useful tool in the face of these challenges. Through this paper, we aim to get an overview of the use of AI in the life cycle of clinical trials. We study how AI can streamline clinical trial management, patient recruitment, real-time patient safety monitoring through portable devices, data analysis from various digital sources, electronic medical records and medical information systems.